Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials
Diabetes Care · 2026
DOI: 10.2337/dc25-1722 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Erik Moedt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HORIZON EUROPE Health.
Abstract (Originalsprache)
OBJECTIVE We evaluated the prognostic and clinical utility of kidneyintelX.dkd, a biomarker-based risk score, in patients with type 2 diabetes and a broad range of chronic kidney disease (CKD) by assessing its association with kidney outcomes at baseline and longitudinally, comparing it with the established Kidney Disease Improving Global Outcomes (KDIGO) risk classification, and examining its responsiveness to canagliflozin. RESEARCH DESIGN AND METHODS We measured tumor necrosis factor receptor-1 (TNFR-1), TNFR-2, and kidney injury molecule-1 (KIM-1) in banked plasma samples at baseline and year 1 and calculated kidneyintelX.dkd scores of participants with CKD G1-G3b from two large randomized controlled trials (Canagliflozin Cardiovascular Assessment Study [CANVAS] and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation [CREDENCE]). We assessed concordance between KDIGO and kidneyintelX.dkd risk levels, evaluated associations of baseline and 1-year changes in kidneyintelX.dkd with kidney outcomes, and examined treatment effects of canagliflozin versus placebo. RESULTS Mean kidneyintelX.dkd scores increased across higher KDIGO risk categories, but individual-level differences revealed improved risk reclassification. The kidneyintelX.dkd score was independently associated with kidney outcomes and more strongly predictive than KDIGO classification. At 1 year, canagliflozin significantly lowered kidneyintelX.dkd score versus placebo, and longitudinal reductions by 1 year were associated with lower subsequent risk of kidney outcomes, independent of changes in estimated glomerular filtration rate or urinary albumin-to-creatinine ratio. Absolute risk reductions with canagliflozin were largest among those at high kidneyintelX.dkd risk. CONCLUSIONS The kidneyintelX.dkd score adds prognostic value beyond clinical classification, reflects canagliflozin treatment response, and helps identify individuals most likely to benefit from therapy. These findings support a role for the kidneyintelX.dkd score in personalized risk assessment and monitoring in type 2 diabetes and CKD in prospective studies and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
- Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.
- Renalytix AI, PLC, New York, NY.
- The George Institute for Global Health, University of South Wales, Sydney, New South Wales, Australia.
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- Department of Internal Medicine, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
ORCID-Profile: Erik Moedt, Clare Arnott, Hiddo J L Heerspink
Förderung
- HORIZON EUROPE Health
Zitieren
APA
Moedt, E., Coca, S. G., Edwards, K., Neuen, B. L., Arnott, C., Bakker, S. J. L., Fleming, F., & Heerspink, H. J. L. (2026). Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials. Diabetes Care. https://doi.org/10.2337/dc25-1722
Vancouver
Moedt E, Coca SG, Edwards K, Neuen BL, Arnott C, Bakker SJL, et al. Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials. Diabetes Care. 2026. doi:10.2337/dc25-1722
BibTeX
@article{Moedt2026,
author = {Moedt, Erik and Coca, Steven G and Edwards, Katherine and Neuen, Brendon L and Arnott, Clare and Bakker, Stephan J L and Fleming, Fergus and Heerspink, Hiddo J L},
title = {Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-1722}
}
EUVIMED